A follow-up survey of clinical and financial health plan leaders uncovers evolving approaches and views on the management of high-cost, curative-intended treatments with one-time administration.
Mark Trusheim
Advertisement
Articles by Mark Trusheim
A look at two surveys that reveal payer perspectives regarding current and future management of high-cost durable therapies with one-time administration.
Advertisement
Latest Updated Articles
Payer Perspectives on Gene Therapy ReimbursementApril 8th 2020
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Responds to FDA’s Warning Letter Regarding 2025 PADE Inspection
2
FDA Reveals New Guidance for Streamlining Biosimilar Development
3
Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12
4
Pharmaceutical Executive Daily: FDA's New Guidance for Biosimilar Development
5